The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

Health secretary Robert F. Kennedy Jr. is proposing to end public comment on decisions made by the U.S. Department of Health ...

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

Affirm Holdings, Inc. , the payment network that empowers consumers and helps merchants drive growth, today announced that Rob O'Hare, CFO of Affirm, will participate in a fireside chat to answer a ...

CCC Intelligent Solutions Holdings Inc. ("CCC") , a leading cloud platform provider for the P&C insurance economy, today announced that Chief Financial Officer, Brian Herb, and Vice President of ...

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.

New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...

Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., JD.com, and AstraZeneca are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...